Pilot Study of Just ASK Training to Increase Breast Cancer Clinical Trial Discussions in Oncology Clinics
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-04-23
80
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a pilot stepped-wedge cluster randomized controlled trial to study the Just ASK21 training program aimed at increasing discussions about cancer clinical trials between healthcare providers and breast cancer patients. The study focuses on assessing the feasibility and acceptability of this trial design, understanding factors influencing training completion, and measuring changes in clinical trial discussion rates before and after the training.
The study involves four clusters of breast cancer care teams, each receiving the web-based Just ASK21 training at different randomized times. This training helps providers recognize assumptions about patient interest and encourages open conversations about clinical trials. Each cluster acts as its own control, with audio recordings of patient-provider encounters collected before and after training to evaluate discussion changes.
Participants include oncology team members and breast cancer patients eligible for clinical trials. The study collects data through audio recordings of visits, analyzing discussion rates and elements linked to trial participation. The main outcome is the rate of clinical trial discussions, measured approximately one year after recruitment ends, with qualitative follow-up to identify factors related to patient trial participation. The trial runs from February 2026 to October 2026.
CONDITIONS
Brief Title
A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical Trials
Research Team
C
Carmen Guerra, MD, MSCE
S
Sejin Lee, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
"Just ASK™" Training (Investigational Arm)
Control (Standard Practice Before Training)
What it is
"Just ASK™" is a web-based provider training module designed to help oncology team members reflect on implicit assumptions about patient clinical trial interest and to promote routine clinical trial discussions with eligible breast cancer patients.
Standard pre-intervention provider practices regarding discussions about clinical trials with eligible breast cancer patients, before the introduction of the "Just ASK™" training.
Role in the trial
Investigational intervention arm, receiving the provider-focused web training as part of the pilot evaluation.
Comparison arm representing provider teams who have not yet been exposed to the "Just ASK™" training.
Primary use or intent
Intended to increase the frequency of provider-patient discussions about eligibility for breast cancer clinical trials by addressing potential provider bias and system barriers.
Providers continue their routine patient interactions related to clinical trial discussions, reflecting baseline practices without specific intervention.
How it is given or performed
Providers access the "Just ASK™" module online and complete web-based training materials focused on clinical trial communication and bias awareness.
Providers receive no special training during this period and conduct patient discussions as per their usual practice.
Evidence maturity and status
Effectiveness of provider implicit bias training for increasing clinical trial discussions is under ongoing evaluation; prior studies of similar educational interventions have shown feasibility for increasing provider self-awareness and potential to improve enrollment equity, but quantitative improvements in provider-patient clinical trial discussions require further proof.
Standard practice has been shown to include barriers to routine clinical trial discussions, with provider-reported obstacles involving time constraints, eligibility perceptions, and implicit assumptions about patient interest; discussion rates remain lower than optimal without structured intervention.
Important limitations
Evidence for real-world improvement in patient outcomes or trial enrollment is limited; observed feasibility and provider engagement do not guarantee sustained discussion changes. Single-center pilot limits generalizability.
Barriers such as time constraints, provider assumptions, and lack of active training on implicit bias may result in missed opportunities for trial discussions with eligible patients.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Members of oncology teams who routinely offer, consent, and enroll breast cancer patients in clinical trials at the Abramson Cancer Center
Able to provide informed consent
Age over 18 years
Diagnosed with breast cancer and potentially eligible for at least one breast cancer treatment clinical trial
Evaluated at the Abramson Cancer Center by participating oncology team members
Able to provide informed consent
You will not qualify if you...
Previously completed the "Just ASK21" training (for oncology team members)
Already consented to participate in a breast cancer clinical trial for treatment (for patient participants)
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Outpatient Treatment
Duration - Varies by cluster timing within the stepped-wedge design
Participants undergo behavioral intervention through web-based "Just ASK™" training designed to help providers increase discussions about breast cancer clinical trials with patients.
Participants complete the web-based training at assigned times; clinical trial discussions occur as part of routine care
Long-term Monitoring
Duration - Up to 12 months after data collection completion
Participants are observed to assess rates of clinical trial discussions and factors associated with breast cancer clinical trial participation.
Follow-up assessments occur based on recorded patient visit data
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Studying Key Non-coding RNAs and Their Interaction With Chromatin Remodeling in Breast Cancer Patients
Comparing 18F-FDG and 68Ga-FAPI-46 PET Scans in Women With ER-positive Breast Cancer
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Observational Study Comparing 3D and 2D Echocardiography for Early Heart Damage Detection in Patients Receiving Anthracyclines and HER2-Targeted Cancer Therapies
Study Comparing 3D-Printed Biodegradable Breast Implants, Traditional Breast-Conserving Surgery, and Silicone Implant Reconstruction for Breast Cancer Patients
Ultrahypofractionated 5-Session Whole Breast Radiotherapy with Boost versus Standard 15-Session Radiotherapy for Breast Cancer Patients with Unfavorable Characteristics
Phase II Study Comparing 5-Day vs. 9-Day Whole Breast Radiotherapy with Boost in Early-stage Breast Cancer
Evaluating 68Ga-FAPI PETCT for Checking Axillary Lymph Node Status After Neoadjuvant Therapy in Women with Breast Cancer
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Exploratory Study of 68Ga-SorB PETCT Imaging to Diagnose Sortilin-Positive Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
An Assessment of the Feasibility and Utility of an ACCC-ASCO Implicit Bias Training Program to Enhance Racial and Ethnic Diversity in Cancer Clinical Trials.